Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B generates $10mm for Anchor Therapeutics

Executive Summary

Anchor Therapeutics Inc. (formerly Ascent Therapeutics; developing pepducin drug candidates that selectively target G protein coupled receptors) has raised $10mm through its Series B financing led by returning shareholders TVM Capital, HealthCare Ventures, and the Novartis Option Fund. The company says that other investors may add money to the round.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies